FUTURE MEMORIES TODAY their experiences. Once you begin to read the stories, you will see how many people are personally affected by these destructive diseases. GE Healthcare is partnering with expert organizations and individuals around the world, including the Alzheimer’s Disease Neuroimaging Initiative, the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing, University College London, The University of Utah, and One Mind for Research. Initial research is focusing on natural history studies to understand AD and the role of imaging-based and other biomarkers. regions of the brain which are most affected by AD. Importantly, hippocampal atrophy at baseline may occur before the changes to the cerebral cortex that result in significant cognitive and memory impairment.
2 A recent clinical study even suggests MRI may help identify individuals who will develop AD nearly a decade before the onset of dementia.
3 The neuroimaging research community was among the earliest adopters of 3.0T and other technologies gaining momentum to enabling high-detail visualization of anatomy, function, and even molecular-scale information.
The MIND campaign (Making an
Impact on Neurodegenerative Diseases),
launched by GE Healthcare, is a global
initiative designed to identify gaps in
current frameworks for the detection,
diagnosis, and care of neurodegenerative
disease, such as AD, dementia, and
Parkinson’s, and to propose viable
Recently, the MIND campaign went
to encourage people touched by
neurodegenerative disease to share
Even in the recent past, diagnosing AD
was largely dependent on somewhat
subjective tests of mental function,
physical neurological exams, and
medical history. Imaging was mostly
utilized to rule out other causes of
dementia. However, a growing body
of clinical studies suggests the role
of imaging may be significantly more
important in the future as a potential
tool for early detection.
DIGITAL DIVE For more information:
At GE, we will continue our work with
our research collaborators to advance
our clinical knowledge of AD and other
neurodegenerative disorders. In parallel,
we are also developing new technologies
such as 7.0T imaging, quantitative tools,
automated motion correction, and novel
pulse sequences in partnership with some
of the leading MR scientists globally.
Beyond technical and clinical research
are other efforts to drive public policy to
support patients, families, and caregivers
affected by neurodegenerative disease,
and to examine ways to reduce the cost
of disease management. These efforts
are truly global and span across France,
Germany, Japan, South Korea, the
United Kingdom, and the United States.
Through GE expertise and innovation,
and in partnership with the scientific
community, I am confident we will
not only confront but lead the way
in making an impact on the lives
of AD patients.
Insight… In a study published last year, GE Healthcare’s arterial spin labeling (3D ASL), a non-invasive MRI perfusion method that quantitatively measures cerebral blood flow per unit tissue mass, revealed an abnormal cerebral perfusion pattern in Parkinson’s disease. All subjects were imaged using a GE Signa* HDxt 3.0T scanner with an eight-channel head coil. This was the first sizeable study to derive a Parkinson’s disease related pattern using 3D ASL MRI. To read the entire paper, visit
1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM.
Forecasting the global burden of Alzheimer’s disease.
Alzheimer’s and Dementia 2007;3:186–191.
2. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD
with MRI-based hippocampal volume in mild cognitive
impairment. Neurology . 1999; 52: 1397–1403.
3. Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ,
Albert MS, Hyman BT, Blacker D, Detoledo-Morrell L. 2011.
Alzheimer-signature MRI biomarker predicts AD dementia
in cognitively normal adults. Neurology 76: 1395–1402.